This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
parkinsons-disease
Parkinson's Disease
Neurodegenerative disease from dopaminergic neuron loss in the substantia nigra; alpha-synuclein Lewy bodies are the pathological hallmark. Cardinal features: bradykinesia, rigidity, resting tremor. Levodopa/carbidopa is mainstay therapy; no disease-modifying therapy approved.
Entry Metadata
| Field | Value |
|---|---|
| ID | parkinsons-disease |
| Name | Parkinson's Disease |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896-912. · PubMed 25904081
- Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839-840. · PubMed 9278044
- Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology. 2009;72(21 Suppl 4):S1-136. · PubMed 19470958